Search

Your search keyword '"Alcantarini, C"' showing total 2 results
Start Over Author "Alcantarini, C" Topic benzimidazoles
2 results on '"Alcantarini, C"'

1. Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV.

Author

Merli M, Rossotti R, Travi G, Ferla F, Lauterio A, Angelini Zucchetti T, Alcantarini C, Bargiacchi O, De Carlis L, and Puoti M

Subjects
Antiviral Agents therapeutic use, Benzimidazoles therapeutic use, Carbamates therapeutic use, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular virology, Drug Combinations, Drug Resistance, Viral genetics, HIV Infections immunology, HIV Infections therapy, Hepacivirus genetics, Hepacivirus immunology, Hepatitis C, Chronic complications, Hepatitis C, Chronic immunology, Hepatitis C, Chronic pathology, Heterocyclic Compounds, 4 or More Rings therapeutic use, Humans, Liver Cirrhosis pathology, Liver Cirrhosis surgery, Liver Cirrhosis virology, Liver Neoplasms pathology, Liver Neoplasms surgery, Liver Neoplasms virology, Male, Middle Aged, Phosphoproteins genetics, Pyrrolidines therapeutic use, Quinoxalines therapeutic use, RNA, Viral genetics, RNA, Viral isolation & purification, Recurrence, Sofosbuvir therapeutic use, Sulfonamides therapeutic use, Sustained Virologic Response, Treatment Failure, Viral Load drug effects, Viral Nonstructural Proteins genetics, Antiviral Agents pharmacology, Benzimidazoles pharmacology, Carbamates pharmacology, HIV Infections complications, Hepacivirus isolation & purification, Hepatitis C, Chronic therapy, Heterocyclic Compounds, 4 or More Rings pharmacology, Liver Transplantation adverse effects, Pyrrolidines pharmacology, Quinoxalines pharmacology, Sofosbuvir pharmacology, Sulfonamides pharmacology
Abstract

Direct-acting antivirals (DAAs) demonstrated high efficacy and safety even in the post-liver transplant (LT) setting and in HIV-infected patients, but data are very limited in the early post-LT period with the most recently available DAA. Two HIV/HCV-coinfected LT recipients (both grafts from HIV/HCV-negative donors) experienced early HCV recurrence with severe hepatitis and were treated with sofosbuvir/velpatasvir for 12 weeks. Unfortunately, both patients failed: one (genotype 4d) showed virological breakthrough at week 3 with resistance-associated substitutions (RASs) for both NS5A and NS5B, while the other (genotype 1a) experienced virological relapse without RAS. Both progressed to fibrosing cholestatic hepatitis and were successfully retreated with glecaprevir/pibrentasvir for 16 weeks achieving sustained virological response. The higher prevalence of RAS in experienced genotype 4 patients and the long time to viral suppression observed in subjects with fibrosing cholestatic hepatitis should be taken into account, considering longer treatment duration to increase the chances of achieving sustained virological response., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2019
Full Text
View/download PDF

2. Sustained virological response with 16‐week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post‐transplant severe HCV recurrence in HIV

Author

Giovanna Travi, Roberto Rossotti, Luciano De Carlis, Andrea Lauterio, Olivia Bargiacchi, Fabio Ferla, Marco Merli, Chiara Alcantarini, Teresa Angelini Zucchetti, Massimo Puoti, Merli, M, Rossotti, R, Travi, G, Ferla, F, Lauterio, A, Angelini Zucchetti, T, Alcantarini, C, Bargiacchi, O, De Carlis, L, and Puoti, M

Subjects
Liver Cirrhosis, Male, Pyrrolidines, Sustained Virologic Response, Sofosbuvir, HIV Infections, Hepacivirus, Viral Nonstructural Proteins, 030230 surgery, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Recurrence, Genotype, Treatment Failure, Sulfonamides, Liver Neoplasms, virus diseases, Hepatitis C, Middle Aged, Viral Load, Pibrentasvir, Drug Combinations, Infectious Diseases, RNA, Viral, 030211 gastroenterology & hepatology, medicine.drug, medicine.medical_specialty, Carcinoma, Hepatocellular, Antiviral Agents, Heterocyclic Compounds, 4 or More Rings, Sofosbuvir/velpatasvir, 03 medical and health sciences, Quinoxalines, Internal medicine, Drug Resistance, Viral, medicine, Humans, NS5A, NS5B, resistance-associated substitution, direct-acting antiviral, Transplantation, business.industry, Glecaprevir, Hepatitis C, Chronic, HIV infection, Phosphoproteins, medicine.disease, Liver Transplantation, liver transplant, chemistry, Benzimidazoles, Carbamates, hepatitis C, business
Abstract

Direct-acting antivirals (DAAs) demonstrated high efficacy and safety even in the post-liver transplant (LT) setting and in HIV-infected patients, but data are very limited in the early post-LT period with the most recently available DAA. Two HIV/HCV-coinfected LT recipients (both grafts from HIV/HCV-negative donors) experienced early HCV recurrence with severe hepatitis and were treated with sofosbuvir/velpatasvir for 12 weeks. Unfortunately, both patients failed: one (genotype 4d) showed virological breakthrough at week 3 with resistance-associated substitutions (RASs) for both NS5A and NS5B, while the other (genotype 1a) experienced virological relapse without RAS. Both progressed to fibrosing cholestatic hepatitis and were successfully retreated with glecaprevir/pibrentasvir for 16 weeks achieving sustained virological response. The higher prevalence of RAS in experienced genotype 4 patients and the long time to viral suppression observed in subjects with fibrosing cholestatic hepatitis should be taken into account, considering longer treatment duration to increase the chances of achieving sustained virological response.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results